Ladenburg downgraded Salarius Pharmaceuticals to Neutral from Buy without a price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SLRX:
- Salarius Pharmaceuticals explores strategic alternatives, begins cost savings
- Salarius Pharmaceuticals reports Q2 EPS ($1.43), consensus ($1.30)
- Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update
- Salarius Pharmaceuticals trading resumes
- Salarius Pharmaceuticals trading halted, news pending